The global Frontotemporal Disorder treatment market is anticipated to showcase considerable growth during the forecast period (2020-2026). The rising orphan drug development initiatives by the FDA, new product launches and the growing geriatric population are some of the key factors contributing to the growth of the global Frontotemporal Disorder treatment market. According to the World Health Organization, in 2019 around 50 million people are living with dementia and the number is anticipated to get three times by 2050. Moreover, nearly 10 million new cases are anticipated to increase every year. According to the WHO, the geriatric population is expected to get double by 2050, when compared to 2000. Globally, in 2000, the proportion of the people aged over 65 years were 11.0% of the global population, and these statistics are expected to reach 22.0% by 2050.
A full report of Frontotemporal Disorder Treatment Market is available at: https://www.omrglobal.com/industry-reports/frontotemporal-disorder-treatment-market
The geriatric population is more susceptible to have this kind of disorder therefore the increasing geriatric population across the globe is promoting the demand of the global frontotemporal disorder treatment market. Treatment of frontotemporal disorder comes under the supervision of the Orphan Drug Act of 1983. This Act comprised of those diseases which affect less than 200,000 people in the US. Europe is also having the same legislation. Therefore, the increase in the orphan drug development initiatives by the FDA and new product approval to be a key factor contributing to the high share of the global frontotemporal disorder treatment market.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/frontotemporal-disorder-treatment-market
For instance, in December 2019, Alector, Inc., a clinical-stage biotechnology company had announced the receiving of US FDA grant of Fast Track designation for its investigational therapeutic, AL001, for the treatment of patients with frontotemporal dementia. AL001 is a kind of human monoclonal antibody which is specifically formed to modulate the secretion of progranulin, a regulator of immune activity in the brain. With this, it is capable to make genetic links to multiple neurodegenerative as Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and so on. AL001 is currently in a Phase 2 trial for the treatment of FTD-GRN and FTD-C9orf72.
In December 2018, TauRx Therapeutics, Inc., neurodegenerative disease research company had received US FDA’s grant Orphan Drug Designation (ODD) to LMTX for the treatment of patients having frontotemporal dementia disorder. LMTX is the first protein aggregation inhibitor to reach Phase 3 clinical development for the treatment of neurodegenerative diseases of the brain.
Global Frontotemporal Disorder Treatment Market Segmentation
By Drug Class
- Cognitive Enhancers
- Antipsychotics
- Antidepressants
- CNS Stimulant
- Other
By Disease Indication
- Frontotemporal Dementia
- Primary Progressive Aphasia
- Movement Disorder
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Others
